Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.57%93.761.3%$988.46m
BIIBBiogen Inc.
-0.35%226.391.3%$918.49m
AMGNAmgen Inc.
-2.74%177.471.3%$453.25m
GILDGilead Sciences, Inc.
-0.47%62.950.9%$425.78m
ILMNIllumina, Inc.
0.11%319.033.5%$281.76m
REGNRegeneron Pharmaceuticals, Inc.
-2.81%333.342.6%$254.55m
VRTXVertex Pharmaceuticals Incorporated
0.71%168.161.9%$234.34m
ALXNAlexion Pharmaceuticals, Inc.
0.08%126.012.0%$171.81m
ONCESpark Therapeutics, Inc.
-0.08%110.6211.2%$168.65m
EXASExact Sciences Corporation
0.44%92.2125.3%$159.85m
SRPTSarepta Therapeutics, Inc.
-1.76%116.6414.7%$146.14m
AAgilent Technologies, Inc.
0.99%76.181.6%$127.24m
INCYIncyte Corporation
-0.48%73.962.5%$94.31m
IONSIonis Pharmaceuticals, Inc.
0.44%72.998.3%$92.09m
BMRNBioMarin Pharmaceutical Inc.
0.98%83.164.3%$89.34m

Company Profile

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.